Oppenheimer Initiates Coverage On Clearside Biomedical With Outperform Rating, Announces Price Target of $5
Oppenheimer Initiates Coverage On Clearside Biomedical With Outperform Rating, Announces Price Target of $5
Oppenheimer以強勁表現的評級啓動了對Clearside Biomedical的覆蓋，並宣佈了5美元的目標股價。
Oppenheimer analyst Andreas Argyrides initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Outperform rating and announces Price Target of $5.
Oppenheimer分析師安德里亞斯·阿吉里德斯開始覆蓋Clearside Biomedical (納斯達克：CLSD)，評級爲Outperform，並宣佈目標價格爲5美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。